As an investor and writer with no financial stake in any of the companies involved, watching the message board battles between Arena (ARNA) and Vivus (VVUS) shareholders is good theater. Both companies have FDA-approved drugs on the market that are effective in helping obese people lose weight, but neither Arena's Belviq nor Vivus's Qsymia look like "the one obesity drug to rule them all". Belviq is hampered by modest efficacy, while Qsymia can produce scary side effects and has a more limited marketing effort behind it.
Quite frankly, though, the Arena-versus-Vivus battle may ultimately be just the undercard for the real battle. A private biotech company by the name of Zafgen has a...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: